Biochemical markers in the follow-up of the osteoporotic patients

Clinical Cases in Mineral and Bone Metabolism

Volumn 9, Issue 2, 2012, Pages 80-84

  Terreni, Alessandro ^a   Pezzati, Paola ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Bone turnover markers; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; HYDROXYPROLINE; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE; PYRIDINIUM DERIVATIVE; RALOXIFENE; TELOPEPTIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE TURNOVER; CHEMICAL ANALYSIS; CLINICAL CHEMISTRY; CLINICAL LABORATORY; CLINICAL PRACTICE; FOLLOW UP; FRACTURE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN CROSS LINKING; REFERENCE VALUE; RISK ASSESSMENT; SHORT SURVEY;

EID: 84867381203     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (51)

1. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
2. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16:229-238. (Pubitemid 40379422)
3. Vasikaran S, Eastell R, Bruyère O, et al. IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.
4. Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008;23:1155-67. (Pubitemid 352040171)
5. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-1053. (Pubitemid 23301484)
6. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005;26:97-122.
7. Cloos PA, Christgau S. Characterization of aged osteocalcin fragments derived from bone resorption. Clin Lab 2004;50:585-598. (Pubitemid 39307369)
8. Garnero P, Grimaux M, Demiaux B, et al. Measurement of serum osteocalcin with a humanspecific two-site immunoradiometric assay. J Bone Miner Res. 1992;7:1389-1398. (Pubitemid 23007084)
9. Diaz Diego EM, Guerrero R, de la Piedra C. Six osteocalcin assays compared. Clin Chem 1994;40:2071-2077. (Pubitemid 24346177)
10. Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19-26.
11. Risteli J, Risteli L. Products of bone collagen metabolism. In: Seibel MJ, Robins SP, Bilezikian JP, eds. Dynamics of bone and cartilage metabolism. 2nd ed. San Diego, USA: Academic press; 1999:275-287.
12. Clowes JA, Hannon RA, Yap TS, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002;30:886-890. (Pubitemid 34616018)
13. Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem 2012. In press.
14. Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest. 2005;28:8-13.
15. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Annu Rev Biochem. 1984;53:717-748. (Pubitemid 14059149)
16. Kamel S, Brazier M, Néri V, et al. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. J Bone Miner Res. 1995;10:1385-1392.
17. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol. 1999;140:332-337. (Pubitemid 29217106)
18. Theis M. Bone markers - their nature and clinical use. JMB 2008;27:117-122. (Pubitemid 351777189)
19. Traba ML, Calero JA, Méndez-Dávila C, et al. Different behaviors of serum and urinary CrossLaps ELISA in the assessment of bone resorption in healthy girls. Clin Chem. 1999;45:682-683. (Pubitemid 29220331)
20. Ivaska KK, Lenora J, Gerdhem P, et al. Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab. 2008;93:2622-2632. (Pubitemid 352008529)
21. Meier C, Meinhardt U, Greenfield JR, et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab. 2006;52:1-10. (Pubitemid 43245859)
22. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, et al. Local communication on and within bone controls bone remodeling. Bone. 2009;44:1026-1033.
23. Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab. 2009;27:265-271.
24. Engin F, Lee B. NOTCHing the bone: insights into multifunctionality. Bone. 2010;46:274-280.
25. O'Brien CA. Control of RANKL gene expression. Bone. 2010;46:911-919.
26. Jabbar S, Drury J, Fordham JN, et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol. 2011;64:354-357.
27. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol. 2005;2:504-517. (Pubitemid 41553935)
28. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31:57-61. (Pubitemid 34754426)
29. Kenny AM, Prestwood KM, Biskup B, et al. Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women. Osteoporos Int. 2004;15:290-294. (Pubitemid 38543947)
30. Marcus R. Exercise: moving in the right direction. J Bone Miner Res. 1998;13:1793-1796. (Pubitemid 28535834)
31. Rauchenzauner M, Schmid A, Heinz-Erian P, et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92:443-449.
32. Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and United States. J Bone Miner Res. 2009;24:389-397.
33. Uebelhart D, Bernard J, Hartmann DJ, et al. Modifications of bone and connective tissue after orthostatic bedrest. Osteopos Int. 2000;11:59-67. (Pubitemid 30099512)
34. Lems WF, Van Veen GJ, Gerrits MI, et al. Effect of low dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumat. 1998;37:27-33.
35. Ton FN, Gunawardene SC, Lee H, et al. Effects of lowdose prednisone on bone metabolism. J Bone Miner Res. 2005;20:464-470. (Pubitemid 40293495)
36. Ivaska KK, Gerdhem P, Akesson K, et al. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res. 2007;22:1155-1164. (Pubitemid 351339697)
37. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-1258. (Pubitemid 41094365)
38. Delmas PD, Munoz F, Black DM, et al. The HORIZON-PFT Research Group. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24:1544-1551.
39. Reginster JY, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone. 2004;34:344-351. (Pubitemid 38177616)
40. Costongs GMPJ, Janson BM, Bas BM, et al. Short-Term and Long-Term Intra-Individual Variations and Critical Differences of Clinical Chemical Laboratory Parameters J Clin Chem Clin Biochem. 1985;23:7-16. (Pubitemid 15140832)
41. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056. (Pubitemid 37294942)
42. Sarkar S, Reginster J-Y, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401. (Pubitemid 38787394)
43. Vasikaran S, Cooper C, Eastell R, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011;24:1271-1274.
44. Smellie WS. What is a significant difference between sequential laboratory results? J Clin Pathol. 2008;6:419-425. (Pubitemid 351518221)
45. Eastell R, Krege JH, Chen P, et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006;22:61-66. (Pubitemid 43106908)
46. Rogers A, Glover SJ, Eastell R. A randomised, doubleblinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone 2009;45:1044-1052.
47. Seibel MJ. Bone: reference bone turnover markers-just a fairy tale? Nat Rev Endocrinol. 2011;26:502-504.
48. Hannon RA, et al. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone. 2004;34:187-194. (Pubitemid 38142448)
49. Meier C, Nguyen TV, Center JR, et al. Bone resorption and osteoporotic fractures in elderly men: the Dubbo osteoporosis epidemiology study. J Bone Miner Res. 2005;20:579-587. (Pubitemid 40393065)
50. Panteghini M. Traceability, reference systems and result comparability. Clin Biochem Rev. 2007;28:97-104.
51. Müller MM. Implementation of reference systems in laboratory medicine. Clin Chem. 2000;46:1907-1909.